The sorry saga of the statins in New Zealand--pharmacopolitics versus patient care.
Begg
Evan
E
Department of Medicine, Christchurch School of Medicine, Christchurch, New Zealand. evan.begg@chmeds.ac.nz
Sidwell
Andrew
A
Gardiner
Sharon
S
Nicholls
Gary
G
Scott
Russell
R
D004345:Drug Industry; D005229:Fatty Acids, Monounsaturated / Q000191:economics / Q000627:therapeutic use; D005252:Fees, Pharmaceutical; D000077340:Fluvastatin; D006077:Government Agencies; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000191:economics / Q000627:therapeutic use*; D007211:Indoles / Q000191:economics / Q000627:therapeutic use; D019458:Insurance Coverage; D007356:Insurance, Pharmaceutical Services; D009313:National Health Programs / Q000191:economics / Q000458:organization & administration*; D009520:New Zealand; D011057:Politics; D017035:Pravastatin / Q000191:economics / Q000627:therapeutic use; D011907:Rate Setting and Review; D019821:Simvastatin / Q000191:economics / Q000627:therapeutic use
D005229:Fatty Acids, Monounsaturated; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D007211:Indoles; D000077340:Fluvastatin; D019821:Simvastatin; D017035:Pravastatin